Investigating the effects of valproic acid on placental epigenetic modifications and development in the CD-1 mouse model
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Gestational exposure to the anticonvulsant drug valproic acid (VPA) is associated with congenital malformations and neurodevelopmental disorders through its action as a histone deacetylase inhibitor. VPA can elicit placental toxicity and affect placental growth and development. The objective of this study was to evaluate the impact of maternal exposure to VPA on the mouse placenta following exposure on gestational day (GD) 13 since previous studies have shown that mice exposed at this time during gestation give birth to offspring with an autism spectrum disorder-like phenotype. We exposed CD-1 dams to a teratogenic dose (600 mg/kg) of VPA or saline on GD13 and assessed fetoplacental growth and development on GD18. We evaluated epigenetic modifications, including acetylated histone H4 (H4ac), methylated H3K4 (H3K4me2) using immunohistochemistry, and global DNA methylation in the placenta at 1, 3, and 24 h following maternal exposure on GD13. In utero exposure to VPA on GD13 significantly decreased placental weight and increased fetal resorptions. Moreover, VPA significantly increased the staining intensity of histone H4 acetylation and H3K4 di-methylation across the placenta at 1 and 3 h post maternal dose. Our results also demonstrate that VPA significantly decreased global DNA methylation levels in placental tissue. These results show that gestational exposure to VPA interferes with placental growth and elicits epigenetic modifications, which may play a vital role in VPA-induced developmental toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:124 |
|---|---|
| Enthalten in: |
Reproductive toxicology (Elmsford, N.Y.) - 124(2024) vom: 26. März, Seite 108551 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jackson, Brianna L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
614OI1Z5WI |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.reprotox.2024.108551 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367710951 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367710951 | ||
| 003 | DE-627 | ||
| 005 | 20240305232243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240128s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.reprotox.2024.108551 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM367710951 | ||
| 035 | |a (NLM)38280688 | ||
| 035 | |a (PII)S0890-6238(24)00018-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jackson, Brianna L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigating the effects of valproic acid on placental epigenetic modifications and development in the CD-1 mouse model |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Gestational exposure to the anticonvulsant drug valproic acid (VPA) is associated with congenital malformations and neurodevelopmental disorders through its action as a histone deacetylase inhibitor. VPA can elicit placental toxicity and affect placental growth and development. The objective of this study was to evaluate the impact of maternal exposure to VPA on the mouse placenta following exposure on gestational day (GD) 13 since previous studies have shown that mice exposed at this time during gestation give birth to offspring with an autism spectrum disorder-like phenotype. We exposed CD-1 dams to a teratogenic dose (600 mg/kg) of VPA or saline on GD13 and assessed fetoplacental growth and development on GD18. We evaluated epigenetic modifications, including acetylated histone H4 (H4ac), methylated H3K4 (H3K4me2) using immunohistochemistry, and global DNA methylation in the placenta at 1, 3, and 24 h following maternal exposure on GD13. In utero exposure to VPA on GD13 significantly decreased placental weight and increased fetal resorptions. Moreover, VPA significantly increased the staining intensity of histone H4 acetylation and H3K4 di-methylation across the placenta at 1 and 3 h post maternal dose. Our results also demonstrate that VPA significantly decreased global DNA methylation levels in placental tissue. These results show that gestational exposure to VPA interferes with placental growth and elicits epigenetic modifications, which may play a vital role in VPA-induced developmental toxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a Placental toxicity | |
| 650 | 4 | |a Teratogen | |
| 650 | 4 | |a Valproic acid | |
| 650 | 7 | |a Valproic Acid |2 NLM | |
| 650 | 7 | |a 614OI1Z5WI |2 NLM | |
| 650 | 7 | |a Histones |2 NLM | |
| 700 | 1 | |a Shafique, Sidra |e verfasserin |4 aut | |
| 700 | 1 | |a Natale, Bryony V |e verfasserin |4 aut | |
| 700 | 1 | |a Natale, David R C |e verfasserin |4 aut | |
| 700 | 1 | |a Winn, Louise M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reproductive toxicology (Elmsford, N.Y.) |d 1995 |g 124(2024) vom: 26. März, Seite 108551 |w (DE-627)NLM012695009 |x 1873-1708 |7 nnns |
| 773 | 1 | 8 | |g volume:124 |g year:2024 |g day:26 |g month:03 |g pages:108551 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.reprotox.2024.108551 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 124 |j 2024 |b 26 |c 03 |h 108551 | ||